Glaucoma continues to be one of the leading causes of blindness worldwide. Although the exact pathogenesis of glaucoma remains elusive and continues to be an active focus of research, elevated intraocular pressure (IOP) is a well-known risk factor. Medical therapy to lower IOP is currently the most commonly utilized initial treatment for primary open-angle glaucoma.
This Focal Points issue reviews evidence-based guidelines in the medical management of glaucoma and summarizes classes of drugs currently available. Because most glaucoma patients require multiple medications, it is essential that clinicians are knowledgeable about medications in terms of their mechanisms of action, side effects, and additivity to one another.
This Focal Points issue will help you understand how to choose a regimen that is effective, safe, tolerable, and affordable to ensure patient acceptance and adherence.
Upon completion of this Focal Points issue, you should be able to:
- Employ evidence-based guidelines in the medical management of glaucoma.
- Discuss the mechanisms of action of various classes of glaucoma medications.
- Identify the side effects of glaucoma medications to provide safe and tolerable care for glaucoma.
Focal Points issues are practical, hands-on discussions of the clinical challenges you face daily. Each issue delivers high-quality, trusted ophthalmic information written and reviewed by leading experts.
Subscribers receive 12 new issues a year, plus access to the Focal Points digital archive.
To access this issue from your laptop or desktop computer, log in to www.aao.org/myonlineproducts with your Academy username and password. To access this issue from your Apple iPad® or Android™ tablet, use the free AAO eBooks app. For more information about the app, visit www.aao.org/ebooks.
The American Academy of Ophthalmology designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.